Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by Quentin30on Sep 17, 2024 6:34pm
60 Views
Post# 36228073

RE:RE:RE:RE:RE:RE:RE:How does Accelerated Approval work

RE:RE:RE:RE:RE:RE:RE:How does Accelerated Approval work what does this have to dpo with ONCY...  we're beyond phase II meetings...  mBC we've now run IND213, and Bracelet-1.

oh wait, yup, now we're planning a third Phase II... ALL this when the FDA 6 years ago granted ONCY a SPA for running a Phase III using Pela + Pax vs Pax alone.

Go and check the company presentation slide deck from Feb 2018...

Page 3
Positive feedback from FDA (EOP2) and EMA (FAL)
One phase 3 study of 450 patients.

Granted Fast Track Designation
Addressing unmet medical need
Expedited and rolling review

154,000+ metastatic breast cancer (mBC) patients > $ Multi Billion

Partnership with Adlai Nortye o Licensing fee and milestones for mBC of
$21.2M Milestone payments of USD $65.4M
Double digit royalty

Hmmm, we had our end of phase II meeting, and FDA said, run a trial with 450 patients... That was 6 and a half years ago... ONCY also had a partner, and royalty milestone payments of 21 million would have been due on treating first Phase III patient.

BUT thanks for copying and pasting about BTD Noteable... now give us aYOUR realistic timeline for AA.
<< Previous
Bullboard Posts
Next >>